Big Pharma

PhRMA Secretly Funds Campaign to Kill Rent Control, per Justice for Renters

Retrieved on: 
Thursday, April 4, 2024
AIDS, Health, Consumer, Public Policy, Government, Residential Building & Real Estate, Pharmaceutical, Advocacy Group Opinion, Professional Services, Construction & Property, Environmental, Social and Governance (ESG), General Health, Seniors, State, Local, Other Policy Issues, Issue, AIDS Healthcare Foundation, Risk, Patient, Greater Los Angeles, Housing, Justice, Big Pharma, AHF, Pharmacy, Advertising, Property management

This latest move is part of an ongoing shell game carried out by PhRMA and the pharmaceutical companies it represents to avoid public scrutiny, including that of the press.

Key Points: 
  • This latest move is part of an ongoing shell game carried out by PhRMA and the pharmaceutical companies it represents to avoid public scrutiny, including that of the press.
  • “This is a shining example of how corporate greed puts both patients and tenants at risk,” said Susie Shannon, campaign manager for Justice for Renters .
  • PhRMA has a PAC called the Pharmaceutical Research and Manufacturers of America California Initiative Fund.
  • That PAC contributed an initial $10,000 to the California Business Roundtable PAC, which in turn contributed $250,000 to Californians to Protect Affordable Housing, a PAC opposing the Justice for Renters Act.

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

Retrieved on: 
Tuesday, March 12, 2024
Patient, SAN, Industry Standard, Compatibility, ISR, Overalls, Corporate title, Big Pharma, Fine chemical

The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader, and Industry Standard Research.

Key Points: 
  • The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader, and Industry Standard Research.
  • Respondents evaluated 98 contract manufacturers across 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey.
  • Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months.
  • With each investment in technology, quality, and facilities, we elevate our capabilities, ensuring we meet and exceed our client's needs.

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

Retrieved on: 
Tuesday, March 12, 2024
Patient, SAN, Industry Standard, Compatibility, ISR, Overalls, Corporate title, Big Pharma, Fine chemical

The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader, and Industry Standard Research.

Key Points: 
  • The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader, and Industry Standard Research.
  • Respondents evaluated 98 contract manufacturers across 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey.
  • Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months.
  • With each investment in technology, quality, and facilities, we elevate our capabilities, ensuring we meet and exceed our client's needs.

A Clinically Proven Alzheimer's Treatment Revealed in a Groundbreaking Documentary Narrated by Michael Bublé

Retrieved on: 
Tuesday, February 13, 2024
Amazon Prime Video, Dementia, Memory, Recode, Grammy Awards, Apple TV, Narration, Vimeo, Big Pharma, NHK, Medicine, Patient, Cognition, Clinical trial, Life, Research

BURLINGAME, Calif., Feb. 13, 2024 /PRNewswire/ -- What if an effective treatment for Alzheimer's disease was already here, and nobody knew about it?

Key Points: 
  • BURLINGAME, Calif., Feb. 13, 2024 /PRNewswire/ -- What if an effective treatment for Alzheimer's disease was already here, and nobody knew about it?
  • Dr. Bredesen currently has a larger, randomized controlled clinical trial underway that is recruiting patients from six locations across the US.
  • Patients following the Bredesen Protocol and Dr Bredesen's ReCODE Program were profiled in the new documentary film, Memories for Life - Reversing Alzheimer's, which is narrated by Grammy-winner Michael Bublé.
  • The film was initially produced for NHK in Japan, where it originally aired, with additional filming, editing, and narration from Michael Bublé included for the North American market.

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

Retrieved on: 
Monday, January 22, 2024
AIM, Tumor microenvironment, Patient, Progression-free survival, MD, Neoplasm, Partnership, Cancer, Big Pharma, RECIST, FOLFIRINOX, Erasmus MC, Blood, Disease, Safety, Toxicity, Doctor of Philosophy, Patent, DLT, Pancreatic cancer, Pharmaceutical industry

Data strongly suggests Ampligen has therapeutic synergy when combined with checkpoint inhibitors — potentially increasing cancer treatment efficacy and subject survival rates.

Key Points: 
  • Data strongly suggests Ampligen has therapeutic synergy when combined with checkpoint inhibitors — potentially increasing cancer treatment efficacy and subject survival rates.
  • A successful DURIPANC Study could make AIM an especially attractive partnership or buyout target for Big Pharma.
  • Strong positive clinical data from the DURIPANC study would also support our belief that Ampligen could synergistically enhance anti-PD-L1 therapies.
  • The primary objective of the Phase 2 portion is to determine the clinical benefit rate of the combination therapy.

Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook

Retrieved on: 
Monday, January 29, 2024
Biometrics, Radiology, Biotechnology, Oncology, Health, Medical Devices, Health Technology, Clinical Trials, Mortality, ChromeOS, Bank statement, Lung cancer screening, HCC, Patient, Machine learning, Imaging, Artificial intelligence, REALITY, Partnership, Cave rescue, COVID-19, MRMC, Stand-alone, ESMO, AI, Lung cancer, Big Pharma, Growth, LCS, Hepatocellular carcinoma, Medical device, AUC, Acceleration, EIB, Small Business Saturday, Hospital, FDA, BofA Securities, Diagnosis, CE, European Investment Bank, Fine chemical

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces its 2023 revenue, outlining both its strategic outlook and key milestones for 2024.
  • Fredrik Brag, Chief Executive Officer and Founder of Median Technologies, commented: "In Q4 2023, our iCRO1 business achieved record-high order intake, which increased significantly our backlog.
  • We expect to return to growth in 2024 on the back of a decline in 2023 revenue due to soft order intake in China caused by the Covid lockdowns in 2022 and H1 2023."
  • The Standalone study will be finalized in Q2 2024 and the MRMC study in Q3 2024.

AHF Urges President Biden to Support WTO IP Waiver

Retrieved on: 
Friday, January 26, 2024
COVID-19, Infectious Diseases, Advocacy Group Opinion, Congressional News, Views, Public Policy, Government, Philanthropy, White House, Federal Government, Pharmaceutical, Health, Foundation, AHF, Public, AIDS Healthcare Foundation, Second Continental Congress, Hoarding, Pandemic, World Trade Organization, Congress, Intellectual property, Big Pharma, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) calls on President Biden to support a proposal for an expanded waiver on intellectual property (IP) rights for COVID-19 treatments and diagnostics currently being advanced at the World Trade Organization (WTO) despite opposition in the U.S. Congress.

Key Points: 
  • AIDS Healthcare Foundation (AHF) calls on President Biden to support a proposal for an expanded waiver on intellectual property (IP) rights for COVID-19 treatments and diagnostics currently being advanced at the World Trade Organization (WTO) despite opposition in the U.S. Congress.
  • “Opposition to the WTO IP waiver by some members of Congress is shortsighted and misplaced.
  • Technological protectionism and vaccine hoarding during the pandemic cost the world millions of lives and trillions of dollars, while Big Pharma made off with record-breaking profits,” said AHF President Michael Weinstein.
  • “We urge President Biden to do the right thing in the name of global health security and public health and support the waiver.

Immorta Bio Welcomes Dr. Vlad Bykoriz as its Chief Medical Officer

Retrieved on: 
Tuesday, January 23, 2024
Disease, Risk management, Patient, MD, Culture, Medical director, Big Pharma, Pfizer, IND, CMO, Doctor of Philosophy, Boehringer Ingelheim, Treating

MIAMI BEACH, Fla., Jan. 23, 2024 /PRNewswire/ -- Immorta Bio, Inc. announced today that Vlad Bykoriz, MD, PhD, has joined the company's management team. Together with other executives, Dr. Bykoriz will be defining the products pipeline and their development strategies. He will be building Immorta Bio preclinical and clinical capabilities, ensuring adherence to ethical guidelines and regulatory compliance, and ultimately helping to bring Immorta Bio innovative therapies to patients.

Key Points: 
  • He will be building Immorta Bio preclinical and clinical capabilities, ensuring adherence to ethical guidelines and regulatory compliance, and ultimately helping to bring Immorta Bio innovative therapies to patients.
  • "We are extremely excited about finding such a strong CMO as Dr. Vlad Bykoriz.
  • Equally important is that, in addition to his professional and managerial skills, Vlad fits into the Immorta Bio organization and culture perfectly."
  • Dr. Vlad Bykoriz received his MD degree from Kiev Medical University and his PhD from the Kiev Institute of Cardiology.

EQS-News: Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Saturday, January 13, 2024
DACH, Incidence, Senior counsel, NPV, Cancer, Algorithm, BGM, EMERGE, CRC, Ministry of Social Affairs, AA, Growth, Collection, Labour, Marketing, PMA, PCR, Education, Physician, Death, Colorectal cancer, AI, Commercial, Genetic testing, Gold, Laboratory, PPV, Therapy, Machine learning, Gene expression, Ageing, Mortality, Patient, Hospital, Traction, Health, Partnership, PHI, FG, Big Pharma, Food, FDA, Biomarker, United Nations, Messenger, Clinical trial, Pancreatic cancer, Pharmaceutical industry

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

Solar Integrated Roofing Corp Answers Investor Questions

Retrieved on: 
Thursday, January 11, 2024
Senior, Fruit, Podcast, Southern California, BESS, Chicago Bears, Insurance, SIRC, Government, Big Pharma, FedRAMP, OTC, Depression, Montross, EV, BPA, PCAOB, SunPower, Sable Systems, Marketing, Research, NFL, Metabolism, Growth, Renewable energy

HENDERSON, Nev., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Solar Integrated Roofing Corp. (OTC: SIRC) (“SIRC” or “the Company”), an integrated, single-source solutions provider of solar power, roofing and EV charging systems answers Investor Questions.

Key Points: 
  • HENDERSON, Nev., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Solar Integrated Roofing Corp. (OTC: SIRC) (“SIRC” or “the Company”), an integrated, single-source solutions provider of solar power, roofing and EV charging systems answers Investor Questions.
  • McKay and Montross brands will be consolidated as the roofing branch and will retain the McKay Roofing name.
  • SIRC is a construction company in the renewable energy space while Balance Claims is an adjusting service function in the roofing industry.
  • Two, SunPower by Milholland is a powerful residential solar brand where we can offer a top-tier solar product at fair margins.